Response of chemotherapy with cisplatin and etoposide versus cisplatin and paclitaxel in advanced non-small cell lung cancer patient
- Conditions
- Advanced non small cell lung cancerNSCLCCisplatinEtoposidePaclitaxel
- Registration Number
- TCTR20181011005
- Lead Sponsor
- Dr. Munshi Md. Arif Hosen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 88
Patients with histology confirmed advanced NSCLC - stage IIIB and stage IV includes liver metastasis, metastasis to opposite lung and pleural effusion
•Patients with other than non-small cell lung cancer.
•Poor performance status: ECOG score >2.
•Those who were not willing.
•Age below 18 years and above 70 years.
•Patients with history of prior chemotherapy or radiotherapy to the chest.
•Initial surgery (excluding diagnostic biopsy) of the primary site.
•Patients with double primaries.
•Pregnant or lactating woman.
•Patient dropped out or lost to follow up before completion of study.
•Serious concomitant medical illness including severe cardiac disease, uncontrolled diabetes mellitus, hypertension or renal diseases.
•Prisoners.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response 1 year clinical and radiological
- Secondary Outcome Measures
Name Time Method Toxicity 1 year Clinical and Biochemical